|
|
 |
 |
| |
 Printable version |
Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center |
Bulletin du Cancer. Volume 88, Number 12, 1213-21, Décembre 2001, Articles originaux
|
 Résumé
Article gratuit
|
Author(s) : Laura Zufferey, Bertrand Roques, Aude Fléchon, Jean-Pierre Droz |
Summary : We have examined 82 patients with hormonoresistant prostate cancer in a retrospective study. Bone and lymph node metastases were observed in 94% and 30% of patients respectively. However, the visceral metastases were frequent: liver (17%), lung (7%), bone marrow (4%), meningitis (4%). PSA is constantly high but 28% of the patients have elevated NSE, which is correlated with lymph node or visceral metastases. ACE is elevated in 27% of cases. Objective and palliative effect of chemotherapy is marked for weekly doxorubicin, prednisone with mitoxantrone and etoposide associated with platin-salts for prostatic carcinoma with neuroendocrine differentiation. This study suggests the presence of different subpopulations of patients with specific evolutive patterns, thus further specific therapy should be evaluated. |
Keywords : prostate cancer, hormonoresistance, neuroendocrine differenciation, chemotherapy. |
|
